SCHEMBL10552185

SCHEMBL10552185

CC(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACE P12821 7/20 0.65
REN P00797 4/20 0.65
LMNA P02545 2/20 0.65
HSD17B10 Q99714 2/20 0.65
KDM4E B2RXH2 1/20 0.65
F2 P00734 1/20 0.65
LTA4H P09960 1/20 0.65
MAPT P10636 1/20 0.65
PEPD P12955 1/20 0.65
ALOX15 P16050 1/20 0.65
PTGS1 P23219 1/20 0.65
HTR2A P28223 1/20 0.65
PTGS2 P35354 1/20 0.65
HRH1 P35367 1/20 0.65
THPO P40225 1/20 0.65
PMP22 Q01453 1/20 0.65
ACE2 Q9BYF1 1/20 0.65
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10552189 1.00 ACE (0.65) ACERENLMNAHSD17B10KDM4E
SCHEMBL7090674 0.87 ACE (0.67) ACERENLMNAHSD17B10KDM4E
SCHEMBL7386429 0.86 ACE (0.55) ACERENLMNAHSD17B10KDM4E
SCHEMBL34461083 0.84 ACE (0.51) ACERENLMNAHSD17B10KDM4E
SCHEMBL10553788 0.84 ACE (0.49) ACERENLMNAHSD17B10KDM4E
SCHEMBL10553796 0.84 ACE (0.49) ACERENLMNAHSD17B10KDM4E
SCHEMBL30905705 0.83 ACE (0.58) ACERENLMNAHSD17B10KDM4E
SCHEMBL3911818 0.83 ACE (0.61) ACERENLMNAHSD17B10KDM4E
SCHEMBL9223327 0.83 ACE (0.61) ACERENLMNAHSD17B10KDM4E
SCHEMBL17352459 0.83 OPRM1 (0.48) ACERENLMNAHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105685-A1 S-Nitrosothiol Compounds and Related Derivatives GALLEON PHARMACEUTICALS, INC. 2010-04-29 US disclosed
US-20100105685-A1 S-Nitrosothiol Compounds and Related Derivatives GALLEON PHARMACEUTICALS, INC. 2010-04-29 US disclosed
WO-2009151744-A1 S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES GALLEON PHARMACEUTICALS, INC. (US) 2009-12-17 WO disclosed
US-4833152-A Anti-hypertensive agents UNIVERSITY OF MIAMI (US) 1989-05-23 US disclosed
US-4745124-A THIO/ESTER PEPTIDES UNIVERSITY OF MIAMI (US) 1988-05-17 US disclosed
US-4734420-A INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME UNIVERSITY OF MIAMI (US) 1988-03-29 US disclosed
US-4692458-A Anti-hypertensive agents UNIVERSITY OF MIAMI (US) 1987-09-08 US disclosed
US-4690936-A AMINO ACIDS, THIOESTER LINKAGE; ANGIOTENSIN INHIBITORS UNIVERSITY OF MIAMI (US) 1987-09-01 US disclosed
EP-0036713-B1 ANGIOTENSIN CONVERTING ENZYME INHIBITORS UNIVERSITY OF MIAMI (US) 1984-01-18 EP disclosed
EP-0036713-A2 Angiotensin converting enzyme inhibitors UNIVERSITY OF MIAMI (US) 1981-09-30 EP disclosed
US-4284779-A Amino acid derivatives E. R. SQUIBB & SONS, INC. (US) 1981-08-18 US disclosed
US-4179434-A Amino acid derivatives E. R. SQUIBB & SONS, INC. (US) 1979-12-18 US disclosed
US-4177277-A INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME E. R. SQUIBB & SONS, INC. (US) 1979-12-04 US disclosed
US-4165320-A Amino acid derivatives E. R. SQUIBB & SONS, INC. (US) 1979-08-21 US disclosed
US-4156786-A Amino acid derivatives E. R. SQUIBB & SONS, INC. (US) 1979-05-29 US disclosed
US-4154960-A Amino acid derivatives E. R. SQUIBB & SONS, INC. (US) 1979-05-15 US disclosed
US-4154946-A Amino mercapto substituted acylamino acids E. R. SQUIBB & SONS, INC. (US) 1979-05-15 US disclosed
US-4146611-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1979-03-27 US disclosed
US-4129571-A Amino acid derivatives E. R. SQUIBB & SONS, INC. (US) 1978-12-12 US disclosed
US-4113715-A Amino acid derivatives E. R. SQUIBB & SONS, INC. (US) 1978-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105685-A1 S-Nitrosothiol Compounds and Related Derivatives NNMT, BHMT2, SQOR ACE 2834/4885REN 2488/4885LMNA 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.